Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1?
Authors:
Open Access
- 29 November 2021
- journal article
- review article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 52 (2) , e13713
Abstract
Background: COVID‐19 and some anti‐SARS‐CoV‐2 vaccines trigger a humoral autoimmune response against a broad range of endogenous components, which may affect recipients’ prognosis in predisposed individuals. Autoantibodies directed against apolipoprotein A‐1 (AAA1 IgG) the major protein fraction of High Density Lipoprotein have been shown to be raised in COVID‐19 and in rheumatoid arthritis (RA) patients and other populations where they have been associated with poorer outcomes. We wanted to assess the impact of anti‐SARS‐CoV‐2 mRNA‐based vaccination on AAA1 autoimmune biomarkers in RA patients.Methods: 20 healthy controls and 77 RA mRNA‐based vaccinated patients were collected at baseline, 3 weeks after the first vaccination, 2 and 8 weeks after the second vaccination. AAA1 and SARS‐CoV‐2 serologies were measured by immunoassays. Systemic and local symptoms occurring during the vaccination protocol were recorded.Results: mRNA‐based vaccination induced a significant increase in median AAA1 IgG levels in both healthy controls and RA patients overtime. However, in both populations, these medians trend did not translate into significant increase in AAA1 IgG seropositivity rates despite evolving from 5 to 10% in healthy controls, and from 9 to 12.9% in RA patients. No associations were retrieved between AAA1 IgG and symptoms of any kind during the vaccination protocol.Conclusions: mRNA‐based vaccination seems to induce a light AAA1 IgG response in immunocompetent individuals within 2 months after the last injection. Although we did not observe any warning signs, the formal demonstration of the harmlessness of such biological warrants further studies.Keywords
Funding Information
- Fondation Centre de Recherches Médicales Carlos et Elsie de Reuter (657)
This publication has 16 references indexed in Scilit:
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationNew England Journal of Medicine, 2021
- Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severityScience, 2020
- COVID-19 vaccine development pipeline gears upThe Lancet, 2020
- Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?Current Pharmaceutical Design, 2019
- Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysisBMJ, 2013
- Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis Care & Research, 2012
- A catalogue of reporting guidelines for health researchEuropean Journal of Clinical Investigation, 2009
- “Prepandemic” Immunization for Novel Influenza Viruses, “Swine Flu” Vaccine, Guillain‐Barré Syndrome, and the Detection of Rare Severe Adverse EventsThe Journal of Infectious Diseases, 2009
- The Central Helices of ApoA-I Can Promote ATP-binding Cassette Transporter A1 (ABCA1)-mediated Lipid EffluxJournal of Biological Chemistry, 2003
- Monitoring Skeletal Changes by Radiological TechniquesJournal of Bone and Mineral Research, 1999